InspireMD’s CGuard™ Embolic Prevention Stent System to be Featured in Clinical Presentations and a Live Case Transmission at LINC 2022

Rhea-AI Summary

InspireMD will showcase its CGuard™ Embolic Prevention System (EPS) at the upcoming LINC 2022 conference in Leipzig, Germany, from June 6-9. The live case transmission aims to exhibit the system's ease-of-use and patient safety features. CEO Marvin Slosman highlighted the significance of the event for engaging with the clinical community. Presentations will feature evidence supporting the superiority of CGuard™ EPS over conventional stents. The conference serves as a vital platform for discussing advancements in vascular medicine.

Positive

• Participation in LINC 2022 enhances visibility among key clinicians.
• Live case transmission demonstrates clinical utility and safety of CGuard™ EPS.

Negative

• None.

Live case transmission designed to demonstrate ease-of-use and exceptional patient safety features of CGuard™ Embolic Prevention System (EPS)

TEL AVIV, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will participate in the Leipzig Interventional Course (LINC) 2022, which is being held June 6-9 in Leipzig, Germany. The company will occupy Booth #36 during the conference.

“We are very pleased to again have a significant presence at this year’s LINC conference, including an opportunity to showcase the CGuard™ EPS stent system in a live case procedure that is designed to demonstrate its clinical utility, design superiority with sustainable protection, resulting in superior patient outcomes and safety,” said Marvin Slosman, chief executive officer of InspireMD. “This unique setting will give interventionalists an opportunity to see CGuard™ EPS in real-time and, we believe, add to the increasing number of clinicians who champion CGuard™ EPS with our unique MicroNet technology.

“We also look forward to talks by Drs. Savr Bugurov and Matteo Stefanini who will review their published evidence demonstrating the superiority of CGuard™ EPS relative to conventional first-generation open stent systems and to Professor Piotr Musialek’s new clinical evidence. The LINC conference continues to be an important platform for our engagement with the global clinical community and we are thrilled to be able to be back to a live format,” Mr. Slosman concluded.   

Details of CGuard™ clinical presentations are as follows:

Date: Monday, June 6^th

Time: 4:15pm – 4:20pm CEST

Room: 3 – Speaker’s Corner

Session: Latest results from clinical trials and innovations: Carotid/Venous/AV

Moderators: Manuela Kohnert, Daniela Branzan

Title: Randomized Controlled Trial of a First-Generation Carotid Stent vs. the MicroNet-Covered Stent: 12-Month Outcomes

Presenter: Savr Bugurov

Date: Wednesday, June 8^th

Time: 11:00am – 11:45am CEST

Room: 1 – Main Arena

Session: Latest Techniques for Carotid Revascularization

Moderator: Dierk Scheinert

Panel: Piotr Musialek, Matteo Stefanini, Ralf Langhoff

11:00am CEST: CGuard Live case transmission from Heart Center, Leipzig, Germany
Operator: Andrej Schmidt

Title: MicroNet-Covered Stent in Stroke Prevention and Treatment: New Evidence
Presenter: Piotr Musialek

Title: Stent properties and vessel adaptability: could these factors influence procedural outcomes?
Presenter: Matteo Stefanini

About LINC
LINC, the LEIPZIG INTERVENTIONAL COURSE is strongly committed to contribute to a systematic scientific evaluation and interdisciplinary discussion of new methods in the field of vascular medicine, allowing conclusions for daily interventional practice. LINC is an interdisciplinary live course, designed to provide a global platform, permitting the discussion of the “vascular patients” by integrating colleagues of different specialties from around the world who are performing endovascular interventions.

For more information, please visit: https://www.leipzig-interventional-course.com/

About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet^® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR.

For more information, please visit www.inspiremd.com.

Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contacts:

Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
craigs@inspiremd.com

Chuck Padala, Managing Director
LifeSci Advisors
646-627-8390
chuck@lifesciadvisors.com
investor-relations@inspiremd.com

FAQ

What is InspireMD showcasing at LINC 2022?

InspireMD is showcasing the CGuard™ Embolic Prevention System (EPS) at LINC 2022.

When is LINC 2022 taking place?

LINC 2022 is taking place from June 6-9, 2022.

What are the key features of CGuard™ EPS?

CGuard™ EPS is designed for ease-of-use and exceptional patient safety.

Where is the LINC 2022 conference located?

LINC 2022 is located in Leipzig, Germany.

What is the ticker symbol for InspireMD?

InspireMD's stock is quoted under the ticker symbol NSPR.